Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Plain Language Summary Publication: Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: Results from an open-label phase Ib ascending dose study

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
Headache The Journal of Head and Face Pain
Date
2024-10-09
Source
OpenAlex
DOI
10.1111/head.14846
PubMed
39382331

Authors

James RuckerMatthew ButlerSadie HambletonCatherine BirdMathieu SeynaeveSanjay CheemaKete Campbell-CokerCarolina MaggioFiona DunbarGiorgio LambruManjit Matharu
Watch author

Derived topics and classifications

psilocybin Chronic PainHeadache / MigrainePharmacologyMechanism of ActionClinical Trial Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Plain Language Summary Publication: Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: Results from an open-label phase Ib ascending dose study2024-10-09

Related papers

Exploring the Therapeutic Potential of Psilocybin: A Comprehensive Review of Clinical Trial Evidence and Implications for Rescheduling.Mini reviews in medicinal chemistry · 2026-09-18Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges.Journal of psychiatric research · 2026-10-01PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-10-01Targeting the serotonin 1B receptor for the treatment of depression and anxiety.Expert opinion on therapeutic targets · 2026-09-28EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEWInternational Journal of Innovative Technologies in Social Science · 2026-09-21Correlation of Ketamine and Classic Psychedelics with Pain-Related Neural Connectivity: A Scoping Review of Clinical Experiments on a Potential Therapeutic Target Concerning Ketamine and Classical Psychedelics Administration for Pain ReliefPsychedelic Medicine · 2026-09-14Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network OrganizationAnesthesia Research · 2026-09-11Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-10-01